HRP20220277T1 - Liječenje fragilnog x sindroma i autizma kanabidiolom - Google Patents
Liječenje fragilnog x sindroma i autizma kanabidiolom Download PDFInfo
- Publication number
- HRP20220277T1 HRP20220277T1 HRP20220277TT HRP20220277T HRP20220277T1 HR P20220277 T1 HRP20220277 T1 HR P20220277T1 HR P20220277T T HRP20220277T T HR P20220277TT HR P20220277 T HRP20220277 T HR P20220277T HR P20220277 T1 HRP20220277 T1 HR P20220277T1
- Authority
- HR
- Croatia
- Prior art keywords
- cannabidiol
- use according
- cbd
- daily
- fragile
- Prior art date
Links
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title claims 35
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title claims 35
- 229950011318 cannabidiol Drugs 0.000 title claims 35
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title claims 35
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title claims 35
- 208000001914 Fragile X syndrome Diseases 0.000 title claims 5
- 206010003805 Autism Diseases 0.000 title 1
- 208000020706 Autistic disease Diseases 0.000 title 1
- 208000013404 behavioral symptom Diseases 0.000 claims 7
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 206010026749 Mania Diseases 0.000 claims 3
- 231100000867 compulsive behavior Toxicity 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010022998 Irritability Diseases 0.000 claims 2
- 206010024264 Lethargy Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 208000027765 speech disease Diseases 0.000 claims 2
- 206010012374 Depressed mood Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- 206010042008 Stereotypy Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 230000003908 liver function Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (15)
1. Kanabidiol za uporabu u postupku liječenja jednog ili više bihevioralnih simptoma fragilnog X sindroma kod subjekta, postupak uključuje:
transdermalno davanje učinkovite količine kanabidiola (CBD) subjektu pri čemu se kod subjekta liječi jedan ili više bihevioralnih simptoma fragilnog X sindroma.
2. Kanabidiol za uporabu prema zahtjevu 1, naznačen time što je učinkovita količina CBD-a
(i) između oko 50 mg i oko 500 mg ukupno dnevno,
(ii) započeto s 50 mg dnevno i titrirano do 500 mg dnevno,
(iii) započeto s 50 mg dnevno i titrirano do 250 mg dnevno,
(iv) započeto s 250 mg dnevno, ili
(v) započeto s 500 mg dnevno.
3. Kanabidiol za uporabu prema zahtjevu 1, naznačen time što je CBD formuliran kao gel, ili kao gel za pojačanu permeaciju.
4. Kanabidiol za uporabu prema zahtjevu 1, naznačen time što se CBD primjenjuje u jednoj dnevnoj dozi, ili u dvije dnevne doze.
5. Kanabidiol za uporabu prema zahtjevu 1, naznačen time što ublažavanje jednog ili više bihevioralnih simptoma fragilnog X sindroma sadrži poboljšanje ukupnog rezultata ljestvice anksioznosti, depresije i raspoloženja (ADAMS), ili poboljšanje jedne ili više mjera aberantne kontrolne liste ponašanja za fragilni X (ABC-FXS).
6. Kanabidiol za uporabu prema zahtjevu 1, naznačen time što je jedan ili više bihevioralnih simptoma odabrano iz skupine koju čine opća anksioznost, društveno izbjegavanje, kompulzivno ponašanje, manično/hiperaktivno ponašanje, razdražljivost, letargija, stereotipnost, i neprikladan govor.
7. Kanabidiol za uporabu prema zahtjevu 1, naznačen time što bihevioralni simptom koji je ublažen je
(i) opća anksioznost,
(ii) društveno izbjegavanje,
(iii) kompulzivno ponašanje,
(iv) manično/hiperaktivno ponašanje,
(v) razdražljivost,
(vi) letargija,
(vii) neodazivost,
(viii) stereotipnost,
(ix) neprimjeren govor,
(x) bijes/raspoloženje, ili
(xi) hiperaktivnost/impulzivnost.
8. Kanabidiol za uporabu prema zahtjevu 1, naznačen time što je CBD
(i) sintetički CBD,
(ii) pročišćeni CBD, ili
(iii) botanički dobiveni.
9. Kanabidiol za uporabu prema zahtjevu 1, naznačen time što transdermalno davanje učinkovite količine kanabidiola (CBD) smanjuje intenzitet najmanje jednog štetnog događaja u odnosu na oralnu primjenu CBD-a, poželjno odabranog iz skupine koju čine pospanost, psihoaktivni učinci, funkcija jetre, i nuspojave povezane s GI.
10. Kanabidiol za uporabu u postupku liječenja jednog ili više bihevioralnih simptoma poremećaja iz autističnog spektra kod subjekta, naznačen time što postupak sadrži transdermalno davanje učinkovite količine kanabidiola (CBD) subjektu.
11. Kanabidiol za uporabu prema zahtjevu 10, naznačen time što je kanabidiol formuliran kao gel, ili kao gel za pojačanu permeaciju.
12. Kanabidiol za uporabu prema zahtjevu 10, naznačen time što se kanabidiol primjenjuje u jednoj dnevnoj dozi, ili u dvije dnevne doze.
13. Kanabidiol za uporabu prema zahtjevu 10, naznačen time što je učinkovita količina kanabidiola između oko 50 mg i oko 500 mg ukupno dnevno ili započeta s 50 mg dnevno i titrirana do 250 mg dnevno.
14. Kanabidiol za uporabu prema bilo kojem od zahtjeva 10 do 13, naznačen time što su jedan ili više bihevioralnih simptoma koji su eliminirani odabrani iz skupine koju čine opća anksioznost, društveno izbjegavanje, kompulzivno ponašanje, manično/hiperaktivno ponašanje, hiperaktivnost, i depresivno raspoloženje.
15. Kanabidiol za uporabu prema bilo kojem od zahtjeva 10 do 14, naznačen time što je kanabidiol sintetički kanabidiol, ili pročišćeni kanabidiol.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762564834P | 2017-09-28 | 2017-09-28 | |
US201862632532P | 2018-02-20 | 2018-02-20 | |
PCT/IB2018/057519 WO2019064234A1 (en) | 2017-09-28 | 2018-09-27 | TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL |
EP18788905.0A EP3687513B1 (en) | 2017-09-28 | 2018-09-27 | Treatment of fragile x syndrome and autism with cannabidiol |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220277T1 true HRP20220277T1 (hr) | 2022-05-13 |
Family
ID=63878731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220277TT HRP20220277T1 (hr) | 2017-09-28 | 2018-09-27 | Liječenje fragilnog x sindroma i autizma kanabidiolom |
Country Status (21)
Country | Link |
---|---|
US (11) | US10213390B1 (hr) |
EP (2) | EP3967301A1 (hr) |
JP (3) | JP7210564B2 (hr) |
KR (2) | KR20220045070A (hr) |
AU (1) | AU2018343256A1 (hr) |
BR (1) | BR112020005918A2 (hr) |
CA (1) | CA3077330A1 (hr) |
CY (1) | CY1125071T1 (hr) |
DK (1) | DK3687513T3 (hr) |
ES (1) | ES2907325T3 (hr) |
HR (1) | HRP20220277T1 (hr) |
HU (1) | HUE058102T2 (hr) |
IL (1) | IL273495A (hr) |
JO (1) | JOP20200082A1 (hr) |
LT (1) | LT3687513T (hr) |
MX (2) | MX2020003606A (hr) |
PL (1) | PL3687513T3 (hr) |
PT (1) | PT3687513T (hr) |
RS (1) | RS62969B1 (hr) |
SI (1) | SI3687513T1 (hr) |
WO (1) | WO2019064234A1 (hr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020005918A2 (pt) | 2017-09-28 | 2020-10-06 | Zynerba Pharmaceuticals, Inc. | tratamento da síndrome do x frágil com canabidiol |
GB201912760D0 (en) * | 2019-09-05 | 2019-10-23 | Healx Ltd | Treatment |
GB2589306A (en) * | 2019-10-25 | 2021-06-02 | Gw Res Ltd | Use of cannabidiol preparations in the treatment of fragile X syndrome |
JP7412583B2 (ja) | 2020-02-07 | 2024-01-12 | ニューロヴェンティ カンパニー リミテッド | リルメニジン化合物を有効成分として含む脆弱x症候群または関連発達障害を治療するための組成物 |
US20210369643A1 (en) * | 2020-05-26 | 2021-12-02 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol |
EP4171528A1 (en) * | 2020-06-29 | 2023-05-03 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome with cannabidiol |
WO2022118290A1 (en) * | 2020-12-03 | 2022-06-09 | Zynerba Pharmaceuticals, Inc. | Cannabidiol for the treatment of refractory seizures |
WO2023070045A1 (en) * | 2021-10-22 | 2023-04-27 | Zynerba Pharmaceuticals, Inc. | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
FI20020333A0 (fi) | 2002-02-20 | 2002-02-20 | Tomi Jaervinen | Metyloidun syklodekstriinin uudet kompleksit |
WO2008060375A2 (en) * | 2006-10-06 | 2008-05-22 | The Regents Of The University Of Californina | Upregulating bdnf levels to mitigate mental retardation |
CA2694325C (en) | 2007-07-30 | 2015-09-22 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
MX2011011514A (es) | 2009-04-28 | 2011-11-18 | Alltranz Inc | Formulaciones de canabidiol y metodos para utilizarlas. |
US20110052694A1 (en) | 2009-08-31 | 2011-03-03 | Alltranz Inc. | Use of cannabidiol prodrugs in topical and transdermal administration with microneedles |
CA2935899C (en) | 2013-01-08 | 2021-08-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Fluorinated cbd compounds, compositions and uses thereof |
EP3001812B1 (en) | 2013-10-29 | 2016-11-02 | Echo Pharmaceuticals B.V. | Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders |
US20160022627A2 (en) | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
CN106999598B (zh) | 2014-05-29 | 2022-02-08 | 鲜切发展有限责任公司 | 稳定的大麻素类化合物制剂 |
US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
US20160271252A1 (en) | 2014-05-29 | 2016-09-22 | Insys Development Company, Inc. | Stable cannabinoid formulations |
US20170224634A1 (en) | 2014-05-29 | 2017-08-10 | Insys Development Company, Inc. | Stable cannabinoid formulations |
AU2015279612A1 (en) | 2014-06-27 | 2017-02-02 | Kenton L. Crowley | Buccal and sublingual cannabinoid formulations and method of making the same |
US20160000843A1 (en) | 2014-07-01 | 2016-01-07 | MJAR Holdings, LLC | High cannabidiol cannabis strains |
EP3209312A1 (en) | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
US9375417B2 (en) | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
US20190125779A1 (en) | 2014-12-30 | 2019-05-02 | University Of Houston System | Pharmaceutical compositions |
US10716766B2 (en) | 2015-03-02 | 2020-07-21 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
US20160338974A1 (en) | 2015-03-02 | 2016-11-24 | Afgin Pharma, Llc | Topical regional neuro affective therapy with cannabinoid combination products |
WO2017068349A1 (en) | 2015-10-23 | 2017-04-27 | E-Therapeutics Plc | Cannabinoid for use in immunotherapy |
WO2017151980A1 (en) | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
US20190070124A1 (en) | 2016-03-04 | 2019-03-07 | Sharon Anavi-Goffer | Compositions of cb2 receptor selective agonists for treatment of mental disorders |
IL301006A (en) | 2016-03-16 | 2023-04-01 | Buzzelet Development And Technologies Ltd | Cannobinoid compounds are rich in terpenes |
GB2549277B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
IL262419B1 (en) | 2016-04-19 | 2024-04-01 | Canna B Cure Ltd | A therapeutic composition containing enzyme-rich cannabis |
TWI790204B (zh) | 2016-06-02 | 2023-01-21 | 加拿大商阿爾宙斯製藥有限公司 | 鼻用大麻素組成物 |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
BR112020005918A2 (pt) | 2017-09-28 | 2020-10-06 | Zynerba Pharmaceuticals, Inc. | tratamento da síndrome do x frágil com canabidiol |
US11458109B2 (en) | 2018-12-14 | 2022-10-04 | Zynerba Pharmaceuticals, Inc. | Treatment of 22Q11.2 deletion syndrome with cannabidiol |
US20210369643A1 (en) | 2020-05-26 | 2021-12-02 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol |
EP4171528A1 (en) | 2020-06-29 | 2023-05-03 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome with cannabidiol |
-
2018
- 2018-09-27 BR BR112020005918-8A patent/BR112020005918A2/pt unknown
- 2018-09-27 JO JOP/2020/0082A patent/JOP20200082A1/ar unknown
- 2018-09-27 KR KR1020227010520A patent/KR20220045070A/ko not_active Application Discontinuation
- 2018-09-27 EP EP21206188.1A patent/EP3967301A1/en active Pending
- 2018-09-27 WO PCT/IB2018/057519 patent/WO2019064234A1/en active Application Filing
- 2018-09-27 ES ES18788905T patent/ES2907325T3/es active Active
- 2018-09-27 AU AU2018343256A patent/AU2018343256A1/en active Pending
- 2018-09-27 JP JP2020517930A patent/JP7210564B2/ja active Active
- 2018-09-27 SI SI201830564T patent/SI3687513T1/sl unknown
- 2018-09-27 EP EP18788905.0A patent/EP3687513B1/en active Active
- 2018-09-27 LT LTEPPCT/IB2018/057519T patent/LT3687513T/lt unknown
- 2018-09-27 DK DK18788905.0T patent/DK3687513T3/da active
- 2018-09-27 HR HRP20220277TT patent/HRP20220277T1/hr unknown
- 2018-09-27 MX MX2020003606A patent/MX2020003606A/es unknown
- 2018-09-27 PT PT187889050T patent/PT3687513T/pt unknown
- 2018-09-27 US US16/144,632 patent/US10213390B1/en active Active
- 2018-09-27 CA CA3077330A patent/CA3077330A1/en active Pending
- 2018-09-27 KR KR1020207012201A patent/KR20200058513A/ko not_active Application Discontinuation
- 2018-09-27 HU HUE18788905A patent/HUE058102T2/hu unknown
- 2018-09-27 RS RS20220123A patent/RS62969B1/sr unknown
- 2018-09-27 PL PL18788905T patent/PL3687513T3/pl unknown
- 2018-12-14 US US16/220,249 patent/US10314792B2/en active Active
-
2019
- 2019-01-16 US US16/249,732 patent/US10471022B2/en active Active
- 2019-05-14 US US16/411,248 patent/US10568848B2/en active Active
- 2019-10-07 US US16/594,317 patent/US10758497B2/en active Active
-
2020
- 2020-01-08 US US16/737,326 patent/US20200214995A1/en not_active Abandoned
- 2020-03-22 IL IL273495A patent/IL273495A/en unknown
- 2020-07-13 MX MX2022012424A patent/MX2022012424A/es unknown
- 2020-08-06 US US16/986,622 patent/US11458110B2/en active Active
-
2021
- 2021-09-02 US US17/465,141 patent/US20220096396A1/en not_active Abandoned
-
2022
- 2022-02-03 JP JP2022015432A patent/JP2022064988A/ja active Pending
- 2022-02-22 CY CY20221100148T patent/CY1125071T1/el unknown
- 2022-08-24 US US17/895,008 patent/US11779549B2/en active Active
-
2023
- 2023-01-10 JP JP2023001500A patent/JP2023040166A/ja active Pending
- 2023-03-21 US US18/124,460 patent/US20230364028A1/en active Pending
- 2023-08-30 US US18/458,727 patent/US20230414533A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220277T1 (hr) | Liječenje fragilnog x sindroma i autizma kanabidiolom | |
Müller et al. | Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer’s disease | |
DOP2017000105A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
CO6251212A2 (es) | Tratamiento terapeutico de sindrome metabolico diabetes tipo 2 obesidad o prediabetes | |
EA201201465A1 (ru) | Лекарственные формы хинонов для лечения офтальмических заболеваний | |
BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
AR043188A1 (es) | Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias | |
CR11724A (es) | Agente para tratar enfermedades | |
MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
CO6771410A2 (es) | Tratamiento terapeutico para el sindrome metabolico, diabetes tipo 2, obesidad o prediabetes | |
ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
Silva et al. | Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression? | |
CO2018009561A2 (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
BR112015010396A2 (pt) | terapia de combinação | |
ECSP088762A (es) | Tratamiento del dolor | |
MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
AR090601A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos | |
BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
Kobayashi et al. | Rapid and lasting enhancement of dopaminergic modulation at the hippocampal mossy fiber synapse by electroconvulsive treatment | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
JP2018511639A5 (hr) | ||
CO2022008001A2 (es) | Métodos para el tratamiento de trastornos depresivos |